PI3Ka/mTOR Inhibitor PKI-179

Preferred Label : PI3Ka/mTOR Inhibitor PKI-179;

NCIt related terms : PKI-179;

NCIt definition : A second generation, small-molecule mimetic of ATP that targets the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. PKI-179 selectively inhibits mTOR and phosphoinositide-3-kinase (PI3K) alpha. By inhibiting the PI3K/mTOR signaling pathway, this agent may inhibit tumor cell proliferation and survival.;

UNII : CNN7Y60164;

InChIKey : WXUUCRLKXQMWRY-OYRHEFFESA-N;

CAS number : 1197160-28-3;

Molecule name : PKI-179;

Détails

Origin ID

C90291;

UMLS CUI

C4552050;

Semantic type(s)
- Organic Chemical [UMLS semantic type]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Phosphatidylinositol 4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform [NCIt concept]
- Serine/Threonine-Protein Kinase mTOR [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients